Survey began 18 August 2004.
Survey Ended 20 October 2004.
Reimportation is a growing and real concern for the pharmaceutical industry and Congress is considering several bills that seek to make drug importation from Canada legal. What’s the best argument against reimportation and is new legislation required? Let us know what your think.
Questions asked:
- In your opinion, if Congress were to pass one of the 2 major reimportation bills, which bill would you prefer to be passed?
- Regardless of the fate of bills in Congress, what’s your level of agreement with the following arguments that have been used against reimportation of prescription drugs?
- Proposed reimportation programs are too complex and expensive
- FDA cannot guarantee safety of reimported drugs
- Risk of endangering patients with counterfeit or substandard drugs
- Would hinder the ability of pharmaceutical companies to invest in R&D for new drugs
- No guarantee reimported drugs would be cheaper after middlemen get their cut
Survey Results:
- Editorial Summary, which presents highlights of selected results (PDF format).
- Interactive Summary of ALL results (de-identified, excludes open-ended responses and comments that may identify the respondent). Allows you to use filters to examine results from different subsets of respondents (e.g., pharma company employees vs. non-pharma people, etc.)
Associated article(s) touching on this topic:
